BRAF and MEK inhibitor therapy eliminates nestin expressing melanoma cells in human tumors Experiment 1 (Melanoma Panel 3.0 Patients All Cells)

To provide single-cell mass cytometry data of melanoma treatment response after dabrafenib and trametinib therapy. This panel dissects melanoma cancer cell heterogeneity to identify subset phenotypes that escape therapy.
Conclusion:
These viSNE analyses were utilized to gate major populations of cells including melanoma (e.g. nestin, SOX2, SOX10, or MHC I negative), leukocytes (e.g. CD45 and MHC I), endothelial cells (CD31 and MHC I), and fibroblast (MHC I/CD90/aSMA).
Notes:
These FCS files were run with viSNE analysis individually with the same set of markers. These events are intact cells pre-gated with histone H3 and rhodium intercalator as a viability agent. This analysis pairs with Figure 1 in the manuscript titled "BRAF and MEK inhibitor therapy eliminates nestin expressing melanoma cells in human tumors". These events are intact cells pre-gated with histone H3 and rhodium intercalator as a viability agent. Fluidigm bead-based normalization was performed before analysis and beads were removed before viSNE analysis.